全文获取类型
收费全文 | 18832篇 |
免费 | 2005篇 |
国内免费 | 66篇 |
专业分类
耳鼻咽喉 | 164篇 |
儿科学 | 529篇 |
妇产科学 | 502篇 |
基础医学 | 2557篇 |
口腔科学 | 368篇 |
临床医学 | 2124篇 |
内科学 | 3748篇 |
皮肤病学 | 188篇 |
神经病学 | 2018篇 |
特种医学 | 754篇 |
外科学 | 2776篇 |
综合类 | 374篇 |
一般理论 | 14篇 |
预防医学 | 1808篇 |
眼科学 | 280篇 |
药学 | 1184篇 |
中国医学 | 6篇 |
肿瘤学 | 1509篇 |
出版年
2021年 | 192篇 |
2020年 | 162篇 |
2019年 | 269篇 |
2018年 | 301篇 |
2017年 | 239篇 |
2016年 | 259篇 |
2015年 | 284篇 |
2014年 | 388篇 |
2013年 | 672篇 |
2012年 | 859篇 |
2011年 | 932篇 |
2010年 | 502篇 |
2009年 | 555篇 |
2008年 | 820篇 |
2007年 | 890篇 |
2006年 | 843篇 |
2005年 | 919篇 |
2004年 | 839篇 |
2003年 | 787篇 |
2002年 | 762篇 |
2001年 | 623篇 |
2000年 | 646篇 |
1999年 | 592篇 |
1998年 | 236篇 |
1997年 | 214篇 |
1996年 | 215篇 |
1995年 | 189篇 |
1994年 | 202篇 |
1993年 | 185篇 |
1992年 | 426篇 |
1991年 | 421篇 |
1990年 | 405篇 |
1989年 | 430篇 |
1988年 | 344篇 |
1987年 | 350篇 |
1986年 | 341篇 |
1985年 | 309篇 |
1984年 | 254篇 |
1983年 | 206篇 |
1982年 | 166篇 |
1981年 | 142篇 |
1980年 | 126篇 |
1979年 | 206篇 |
1978年 | 173篇 |
1977年 | 135篇 |
1976年 | 140篇 |
1974年 | 173篇 |
1973年 | 138篇 |
1972年 | 152篇 |
1971年 | 138篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Jon C. Tilburt MD David Zahrieh PhD Joel E. Pacyna MA Daniel G. Petereit MD Judith S. Kaur MD Bruce D. Rapkin PhD Robert L. Grubb III MD George J. Chang MD Michael J. Morris MD Evan Z. Kovac MD Kara N. Babaian MD Jeff A. Sloan PhD Ethan M. Basch MD Elizabeth S. Peil MHA Amylou C. Dueck PhD Paul J. Novotny MS Electra D. Paskett PhD Jan C. Buckner MD Daniel D. Joyce MD Victor M. Montori MD Dominick L. Frosch PhD Robert J. Volk PhD Simon P. Kim MD 《Cancer》2022,128(6):1242-1251
3.
Viral infections form a substantial part of the intensive care workload, even before the recent and ongoing COVID-19 pandemic. The growing availability of molecular diagnostics for viral infections has led to increased recognition of these pathogens. This additional information, however, provides new challenges for interpretation and management. As the SARS-CoV-2 pandemic has amply demonstrated, the emergence and global spread of novel viruses are likely to provide continued challenges for critical care physicians into the future. This article will provide an overview of viral infections relevant to the critical care physician, discussing the diagnosis and management of respiratory viral infections, blood borne and enteric viruses. We will also discuss herpesviridae complications, commonly seen due to reactivation of latent infections. Further, we explore some rarer and emerging viruses, including recognition of viral haemorrhagic fevers, and briefly discuss post-viral syndromes which may present to the intensive care unit. Finally, we will discuss infection control and its importance in preventing nosocomial viral transmission. 相似文献
4.
5.
6.
7.
Carly Jade Carter Ahmed H Mekkawy David L Morris 《World journal of gastroenterology : WJG》2021,27(40):6844-6860
The prognosis of pancreatic cancer is poor with the overall 5-year survival rate of less than 5% changing minimally over the past decades and future projections predicting it developing into the second leading cause of cancer related mortality within the next decade. Investigations into the mechanisms of pancreatic cancer development, progression and acquired chemoresistance have been constant for the past few decades, thus resulting in the identification of human nucleoside transporters and factors affecting cytotoxic uptake via said transporters. This review summaries the aberrant expression and role of human nucleoside transports in pancreatic cancer, more specifically human equilibrative nucleoside transporter 1/2 (hENT1, hENT2), and human concentrative nucleoside transporter 1/3 (hCNT1, hCNT3), while briefly discussing the connection and importance between these nucleoside transporters and mucins that have also been identified as being aberrantly expressed in pancreatic cancer. The review also discusses the incidence, current diagnostic techniques as well as the current therapeutic treatments for pancreatic cancer. Furthermore, we address the importance of chemoresistance in nucleoside analogue drugs, in particular, gemcitabine and we discuss prospective therapeutic treatments and strategies for overcoming acquired chemoresistance in pancreatic cancer by the enhancement of human nucleoside transporters as well as the potential targeting of mucins using a combination of mucolytic compounds with cytotoxic agents. 相似文献
8.
9.
Rebecca C. Gosling Paul D. Morris Daniel A. Silva Soto Patricia V. Lawford D. Rodney Hose Julian P. Gunn 《JACC: Cardiovascular Imaging》2019,12(5):865-872
ObjectivesThis study sought to assess the ability of a novel virtual coronary intervention (VCI) tool based on invasive angiography to predict the patient’s physiological response to stenting.BackgroundFractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) is associated with improved clinical and economic outcomes compared with angiographic guidance alone. Virtual (v)FFR can be calculated based upon a 3-dimensional (3D) reconstruction of the coronary anatomy from the angiogram, using computational fluid dynamics (CFD) modeling. This technology can be used to perform virtual stenting, with a predicted post-PCI FFR, and the prospect of optimized treatment planning.MethodsPatients undergoing elective PCI had pressure-wire–based FFR measurements pre- and post-PCI. A 3D reconstruction of the diseased artery was generated from the angiogram and imported into the VIRTUheart workflow, without the need for any invasive physiological measurements. VCI was performed using a radius correction tool replicating the dimensions of the stent deployed during PCI. Virtual FFR (vFFR) was calculated pre- and post-VCI, using CFD analysis. vFFR pre- and post-VCI were compared with measured (m)FFR pre- and post-PCI, respectively.ResultsFifty-four patients and 59 vessels underwent PCI. The mFFR and vFFR pre-PCI were 0.66 ± 0.14 and 0.68 ± 0.13, respectively. Pre-PCI vFFR deviated from mFFR by ±0.05 (mean Δ = ?0.02; SD = 0.07). The mean mFFR and vFFR post-PCI/VCI were 0.90 ± 0.05 and 0.92 ± 0.05, respectively. Post-VCI vFFR deviated from post-PCI mFFR by ±0.02 (mean Δ = ?0.01; SD = 0.03). Mean CFD processing time was 95 s per case.ConclusionsThe authors have developed a novel VCI tool, based upon the angiogram, that predicts the physiological response to stenting with a high degree of accuracy. 相似文献
10.
Alex C. Scibetta Elizabeth R. Morris Andrea B. Liebowitz Xueqin Gao Aiping Lu Marc J. Philippon Johnny Huard 《Journal of orthopaedic research》2019,37(6):1339-1349
People of all backgrounds are susceptible to bone and cartilage damage, and these injuries can be debilitating. Current treatments for bone and cartilage injuries are less than optimal, and we are interested in developing new approaches to treat these diseases, specifically using human muscle‐derived stem cells (hMDSCs). Our lab previously demonstrated that sex differences exist between male and female murine MDSCs; thus, this paper sought to investigate whether sex differences also exist in hMDSCs. In the present study, we characterized the chondrogenic and osteogenic sex differences of hMDSCs in vitro and in vivo. We performed in vitro osteogenic and chondrogenic differentiation using hMDSC pellet cultures. As demonstrated by microCT, histology, and immunohistochemistry, male hMDSCs were more chondrogenic and osteogenic than their female counterparts in vitro. No differences were observed based on the sex of hMDSCs in osteogenic and chondrogenic gene expression and cell surface markers. For our in vivo study, we transduced hMDSCs with lenti‐BMP2/GFP and transplanted these cells into critical‐sized calvarial defects in mice. MicroCT results revealed that male hMDSCs regenerated more bone at 2 weeks and demonstrated higher bone density at 4 and 6 weeks than female hMDSCs. Histology demonstrated that both male and female hMDSCs regenerated functional bone. Clinical relevance: These studies reinforce that stem cells isolated from male and female patients differ in function, and we should disclose the sex of cells used in future studies. Considering sex differences of hMDSCs may help to improve cell‐based therapies for autologous cell treatment of bone and cartilage damage. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:1339–1349, 2019. 相似文献